Medical Research

At CAF, Medical Research is Key

Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.

CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.

Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.





FDA Approves bluebird bio’s ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia

zynteglo approved for beta-thalassemia

bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.

Read more



CAF Accepting Applications for 2022 Medical Research Grants & Fellowships

November 3, 2021 – The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia. The awards are in three categories: Support for Ongoing Clinical Research in Thalassemia Research Fellowships Clinical Trials in Thalassemia Cell and Gene Therapy Details are as follows: Support for Ongoing Clinical Research in […]

Read more



Orchard Therapeutics Presents Positive Results from Gene Therapy Trial for Beta Thalassemia

May 1, 2019 – This past Monday at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C., Orchard Therapeutics presented positive results from its gene therapy trial for the treatment of beta thalassemia. During this study, nine transfusion-dependent beta thalassemia patents received OTL-300 gene therapy treatment, and all nine treated […]

Read more


CAF Awards $227,500 Funding in Medical Research Fellowships

CAF is pleased to announce that five new Cooley’s Anemia Foundation Medical Research Fellowships and two renewal Fellowships have been awarded for the 2018-2019 grant cycle. The total amount of funding for the 7 research Fellowships is $227,500. These Fellowship recipients were assessed on the basis of the quality of the scientific content, the academic […]

Read more


ApoPharma’s START Study Now Recruiting Participants

September 20, 2018 – The START study is examining the effects of giving early treatment of deferiprone to young children with beta thalassemia who have started receiving regular blood transfusions but have not yet reached the criteria for starting on iron chelation therapy. There are 2 trial sites in the US: Los Angeles and Philadelphia. Learn […]

Read more


Secured By miniOrange